By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

RegeneRx Biopharmaceuticals, Inc. 

3 Bethesda Metro Center, Suite 630

Bethesda  Maryland  20814  U.S.A.
Phone: 301-280-1992 Fax: 301-280-1996


SEARCH JOBS








Company News
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Israeli Patent For Treating And Repairing Heart Damage 2/25/2015 9:15:55 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Updates Website 2/19/2015 11:49:17 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Releases Letter To Shareholders 2/17/2015 12:13:51 PM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Partner Submits Phase 2B/3 IND To Korean Health Authority For RGN-259 For The Treatment Of Dry Eye Syndrome 12/29/2014 7:48:08 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report Thymosin Beta 4 Is Cardioprotective In Pulmonary Hypertension/Heart Failure Model 11/25/2014 9:30:39 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 10/24/2014 9:23:31 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Dr. Michael Chopp Reports On Successful Remodeling Of The Central And Peripheral Nervous Systems After Injury/Disease Using Thymosin Beta 4 10/23/2014 11:28:09 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Allowed To Proceed With Phase 3 Using RGN-259 Eye Drops For The Treatment Of Neurotrophic Keratopathy 10/20/2014 8:27:43 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Canadian Patent For Inhibition Or Reversal Of Skin Aging 9/30/2014 9:16:22 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives $1 Million Pursuant To Product License And Stock Purchase Agreement 9/3/2014 12:06:40 PM
12345678910...
//-->